Experience

Davis Polk advised the representative of the initial purchasers on a Rule 144A/Regulation S offering by Hologic, Inc. of $350 million aggregate principal amount of its 4.375% senior…

Davis Polk advised the joint book-running managers and representatives of the underwriters on the $201 million public offering by BeiGene, Ltd. of American Depositary Shares. The ADSs…

Davis Polk is advising PharMerica Corporation on its approximately $1.4 billion acquisition by a newly formed company controlled by KKR, with Walgreens Boots Alliance, Inc. as a minority…

Davis Polk advised the sole book-running manager in connection with Galapagos NV’s offering of 4,312,500 ordinary shares in the form of American depositary shares, which includes the full…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Evolent Health, Inc. of $125 million aggregate principal amount of its 2.00% senior convertible notes…

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by AbbVie Inc. of €3.6 billion aggregate principal amount of senior notes in three…

Davis Polk advised the representatives of the several underwriters, in connection with a secondary offering of 7,500,000 shares of Class A common stock of Evolent Health, Inc. by certain of…

Davis Polk is advising Aetna Inc. in connection with the sale by Aetna and Humana Inc. of certain of their respective Medicare Advantage assets to Molina Healthcare, Inc. for a total…

Davis Polk advised the joint book-running managers in connection with the $120 million follow-on offering of common stock of Global Blood Therapeutics, Inc. Global Blood’s common stock is…

Davis Polk advised the joint book-running managers and representatives of the underwriters in the $182.2 million initial public offering by BeiGene, Ltd. of 7,590,000 American Depositary…